First-in-Human Trial of DLL3-Targeted ADC SHR-4849 Shows Promise in Relapsed SCLC

SHR-4849, an antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3), demonstrated encouraging results in its first-in-human Phase 1 trial for relapsed small cell lung cancer patients. The selective targeting approach achieved notable tumor responses, offering a potential new therapeutic option for this aggressive cancer subtype with limited treatments.